SCHEMBL6991677

SCHEMBL6991677

CC(C)(C)OC(=O)N1C(=O)CC(=O)C[C@@H]1Cc1cccc(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
STS P08842 2/20 0.39
CTSL P07711 1/20 0.39
KLK7 P49862 6/20 0.39
NR1H2 P55055 2/20 0.38
NR1H3 Q13133 2/20 0.38
KLK5 Q9Y337 5/20 0.37
PRSS1 P07477 2/20 0.37
PRSS2 P07478 2/20 0.37
PRSS3 P35030 2/20 0.37
TP53 P04637 2/20 0.37
CETP P11597 1/20 0.36
P2RX7 Q99572 1/20 0.36
GRM5 P41594 1/20 0.36
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3206265 0.86 KLK7 (0.50) STSKLK7NR1H2NR1H3KLK5
SCHEMBL10132370 0.78 ALDH1A1 (0.50) SMN1; SMN2STSNR1H2NR1H3P2RX7
SCHEMBL247530 0.76 KLK7 (0.54) STSKLK7NR1H2NR1H3KLK5
SCHEMBL14932460 0.75 GRM2 (0.41) SMN1; SMN2STSKLK7NR1H2NR1H3
SCHEMBL22266043 0.75 SMN1; SMN2 (0.50) HSD17B2SMN1; SMN2STSNR1H2TP53
SCHEMBL31080065 0.74 GLA (0.38) SMN1; SMN2KLK7NR1H2KLK5PRSS1
SCHEMBL1519933 0.73 SMN1; SMN2 (0.45) HSD17B2SMN1; SMN2STSCTSLNR1H2
SCHEMBL1519935 0.73 SMN1; SMN2 (0.45) HSD17B2SMN1; SMN2STSCTSLNR1H2
SCHEMBL3161476 0.73 SMN1; SMN2 (0.58) SMN1; SMN2STSTP53POLB
SCHEMBL16787408 0.72 MAPT (0.42) KLK7NR1H2NR1H3KLK5GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889683-B2 Substituted quinoxalines as inhibitors of fatty acid binding protein MERCK SHARP & DOHME CORP. (US) 2014-11-18 US disclosed
US-8889683-B2 Substituted quinoxalines as inhibitors of fatty acid binding protein MERCK SHARP & DOHME CORP. (US) 2014-11-18 US disclosed
US-20120122837-A1 INHIBITORS OF FATTY ACID BINDING PROTEIN MERCK SHARP & DOHME LLC 2012-05-17 US disclosed
US-20120122837-A1 INHIBITORS OF FATTY ACID BINDING PROTEIN MERCK SHARP & DOHME LLC 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122837-A1 INHIBITORS OF FATTY ACID BINDING PROTEIN FABP4, FABP1, FABP3 HSD17B2 1758/4885SMN1; SMN2 4592/4885STS 4531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.